Trust Company of Vermont’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Trust Company of Vermont’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-179	Closed	-$18.4K	–	871
2023 Q2	$18.4K	Hold	179	–	–	﹤0.01%	596
2023 Q1	$19.5K	Hold	179	–	–	﹤0.01%	605
2022 Q4	$20.4K	Hold	179	–	–	﹤0.01%	576
2022 Q3	$11K	Hold	179	–	–	﹤0.01%	709
2022 Q2	$14K	Buy	+179	New	+$17K	﹤0.01%	633

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Trust Company of Vermont's HZNP Position: Q3 2023 in Review

Trust Company of Vermont sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 179 shares — an estimated $18.4K sold.

Trust Company of Vermont first reported a position in HZNP in Q2 2022 and held it in 5 quarters. The position peaked at $20.4K in Q4 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Trust Company of Vermont reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Trust Company of Vermont sold 179 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $18.4K.
Trust Company of Vermont first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022 and held it in 5 quarters.
Trust Company of Vermont's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $20.4K in Q4 2022.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Trust Company of Vermont's 13F filing for Q3 2023, filed 27 Nov 2023.